1. In Vivo
  2. >>Business Strategy

Pharmion's Euro Bet Pays Off

Celgene's $2.9 billion cash and stock offer for Pharmion proves that Pharmion's decision to tackle Europe--not a popular choice among US-based spec pharma--has paid off handsomely. Pharmion is Celgene's European partner on Thalomid; now Celgene gets 100% of the drug's economics right before launch. The deal may have come as a surprise to Wall Street, but it makes sense.

While speculation swirled around who would buy Biogen Idec Inc. and whether Genzyme Corp. would be next, out comes Celgene Corp. on November 19 with a $2.9 billion cash and stock offer for specialty pharma firm Pharmion Corp. , made up of 35% cash and 65% equity, at an almost-50% premium to the previous working day’s close. [See Deal] "We didn’t see this coming," admitted Citigroup analyst Yaron Werber, MD, on the conference call following the announcement.

Neither did we. But the deal makes sense. It’s another case of licenser buying licensee; Pharmion had in 2001 acquired...

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.